Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02001025
Other study ID # Absorb/Xience 01
Secondary ID
Status Recruiting
Phase N/A
First received November 27, 2013
Last updated November 27, 2013
Start date November 2013

Study information

Verified date November 2013
Source Medical University of Vienna
Contact Daniel Dalos, MD
Phone +43 1 40400 4614
Email daniel.dalos@meduniwien.ac.at
Is FDA regulated No
Health authority Austria: Ethikkommission
Study type Observational

Clinical Trial Summary

The biodegradable ABSORB scaffold is characterized by a greater strut thickness, but it has a greater flexibility compared to the XIENCE stent. Due to its fragility the inflating pressure of the ABSORB scaffold is limited and suitable lesions have to be well prepared. This study assesses the incidence of malapposed stent-struts, and the frequency of stent-underexpansion and edge dissection after ABSORB implantation compared to the XIENCE stent.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria for implanting an Absorb scaffold:

- age < 55 years OR

- lesion length > 24mm OR

- multiple lesions to be treated

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
Absorb scaffold

Xience stent


Locations

Country Name City State
Austria Medical University of Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Rudolf Berger

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary adverse post-stenting results Malapposition, underexpansion and edge dissections assessed with Optical Coherence Tomography (OCT) 1 year No